BioCentury
ARTICLE | Clinical News

Nexvax2: Phase Ib started

September 10, 2012 7:00 AM UTC

ImmusanT began a double-blind, placebo-controlled, Australian and New Zealand Phase Ib trial to evaluate multiple ascending-doses of intradermal Nexvax2 in about 84 patients. Becton Dickinson and Co. (NYSE:BDX, Franklin Lakes, N.J.) is supplying to ImmusanT intradermal injection solutions to administer Nexvax2. ImmusanT will also use its companion diagnostic technology to identify candidates for the vaccine. ...